Volume : 09, Issue : 10, October – 2022

Title:

40.UNDERSTANDING THE PATHOPHYSIOLOGY AND MANAGEMENT OF CHF WITH REDUCED EJECTION FRACTION
‬

Authors :

Naveena.B*, Vimalesh.M , Melwin raj.A , Anusahaya supriya

Abstract :

Coronary heart failure (HF) is a medical syndrome because of structural and practical defects in the myocardium resulting in impairment of ventricular filling or the ejection of blood. Heart failure with reduced ejection fraction is defined as a circumstance wherein the coronary heart fails to discharge its contents accurately or a pathophysiological country in which an abnormality of cardiac feature caused the failure of the heart to pump blood at a fee commensurate with the necessities of the metabolizing tissues. The ESC HF guidelines list pathological myocardial injury (coronary artery disease, cardiomyopathies, viral infection, and toxins), abnormal loading conditions (arterial hypertension and valvular diseases), and arrhythmias (tachyarrhythmias and bradyarrhythmia) as the principal etiology of HFrEF.Risk elements are man or woman traits, attributes, or co-taking place illnesses. Cardiac situations which include diabetes mellitus, persistent kidney sickness, and anemia; and affected person traits which include the male gender and older age. This remains the cornerstone of the management of HFrEF. Frontline medical therapy for HFrEF is ACE inhibitors, Beta blockers, and diuretics for symptomatic relief. If still symptomatic and LVEF ≤35%, Spironolactone may be added. If still symptomatic and LVEF ≤35% ARNI should replace ACE inhibitors, and Ivabradine or cardiac resynchronization therapy should be considered. If still symptomatic digoxin, LV assist device or heart transplantation should be considered. Specially trained HF interprofessional team is essential for patients with HF. Primary care medical providers and cardiologists must coordinate care to minimize any adverse outcomes of medical therapy and prevent the progression of this disease.
KEY WORDS: CHF, HFrEF, Epidemiology, ACE inhibitors

Cite This Article:

References:

1. Inamdar AA, Inamdar AC. Heart failure: diagnosis, management and utilization. Journal of clinical medicine. 2016 Jun 29;5(7):62.
2. Ohtani T, Mohammed SF, Yamamoto K, Dunlay SM, Weston SA, Sakata Y, Rodeheffer RJ, Roger VL, Redfield MM. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. European heart journal. 2012 Jul 1;33(14):1742-9.
3. Maeder MT, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. Journal of the American College of Cardiology. 2010 Sep 7;56(11):855-63.
4. Dassanayaka S, Jones SP. Recent developments in heart failure. Circulation research. 2015 Sep 11;117(7):e58-63.
5. Albakri A. Heart Failure with Reduced Ejection Fraction: A Review of Clinical Status and Meta-Analyses of Diagnosis by 3D Echocardiography and Natriuretic Peptides-Guided Heart Failure Therapy. Trends Res. 2018 Nov 22;1.
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37: 2129-2200
7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013 Oct 15;62(16):e147-239.
8. Tiller D, Russ M, Greiser KH, Nuding S, Ebelt H, Kluttig A, Kors JA, Thiery J, Bruegel M, Haerting J, Werdan K. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population–the CARLA study. PloS one. 2013 Mar 15;8(3):e59225.
9. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nature Reviews Cardiology. 2016 Jun;13(6):368-78.
10. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nature Reviews Cardiology. 2011 Jan;8(1):30-41.
11. Friedberg CK. Diseases of the Heart. Academic Medicine. 1950 Mar 1;25(2):159.
12. Braunwald E. Clinical manifestations of heart failure. Heart disease. 1980.
13. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009 Jun 23;119(24):3070-7.
14. Albakri A. Heart Failure with Reduced Ejection Fraction: A Review of Clinical Status and Meta-Analyses of Diagnosis by 3D Echocardiography and Natriuretic Peptides-Guided Heart Failure Therapy. Trends Res. 2018 Nov 22;1.
15. Lodge FM, Yousef Z. The pathophysiology of heart failure. Primary Care Cardiovascular Journal. 2016:S12-6.
16. Varshney AS, Berg DD, Katz JN, Baird-Zars VM, Bohula EA, Carnicelli AP, Chaudhry SP, Guo J, Lawler PR, Nativi-Nicolau J, Sinha SS. Use of temporary mechanical circulatory support for management of cardiogenic shock before and after the united network for organ sharing donor heart allocation system changes. JAMA cardiology. 2020 Jun 1;5(6):703-8.
17. Zealand KT. INDEX 2012. Kai Tiaki Nursing New Zealand. 2013 Jul;19(6).
18. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000 Jun 27;101(25):2981-8.
19. Lieben Louis X, Meikle Z, Chan L, DeGagne G, Cummer R, Meikle S, Krishnan S, Yu L, Netticadan T, Wigle JT. Divergent effects of resveratrol on rat cardiac fibroblasts and cardiomyocytes. Molecules. 2019 Jul 17;24(14):2604.
20. Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart failure reviews. 2016 Mar;21(2):169-76.
21. Sousa-Pinto B, Ferreira-Pinto MJ, Santos M, Leite-Moreira AF. Central nervous system circuits modified in heart failure: pathophysiology and therapeutic implications. Heart failure reviews. 2014 Nov;19(6):759-79.
22. Friedberg CK. Diseases of the Heart. Academic Medicine. 1950 Mar 1;25(2):159.
23. Eyuboglu M. Prognostic factors in the heart failure with reduced ejection fraction. International Journal of Cardiology. 2017 May 15;235:187.
24. McKelvie RS, Moe GW, Ezekowitz JA, Heckman GA, Costigan J, Ducharme A, Estrella-Holder E, Giannetti N, Grzeslo A, Harkness K, Howlett JG. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Canadian Journal of Cardiology. 2013 Feb 1;29(2):168-81.
25. Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73.
26. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, Mant D, McManus RJ, Holder R, Deeks J, Fletcher K. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health technology assessment (Winchester, England). 2009 Jan 1;13(32):1-207.
27. Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: the CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). Journal of the American College of Cardiology. 2013 Nov 12;62(20):1845-54.
28. Wong CM, Hawkins NM, Petrie MC, Jhund PS, Gardner RS, Ariti CA, Poppe KK, Earle N, Whalley GA, Squire IB, Doughty RN. Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European heart journal. 2014 Oct 14;35(39):2714-21.
29. Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem?. Cardiology clinics. 2007 Nov 1;25(4):487-95.
30. Gerber Y, Weston SA, Enriquez-Sarano M, Manemann SM, Chamberlain AM, Jiang R, Roger VL. Atherosclerotic burden and heart failure after myocardial infarction. JAMA cardiology. 2016 May 1;1(2):156-62.
31. Gerber Y, Weston SA, Berardi C, McNallan SM, Jiang R, Redfield MM, Roger VL. Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. American journal of epidemiology. 2013 Oct 15;178(8):1272-80.
32. Vedin O, Lam CS, Koh AS, Benson L, Teng TH, Tay WT, Braun OÖ, Savarese G, Dahlström U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circulation: heart failure. 2017 Jun;10(6):e003875.
33. Allen LA, Magid DJ, Gurwitz JH, Smith DH, Goldberg RJ, Saczynski J, Thorp ML, Hsu G, Sung SH, Go AS. Risk factors for adverse outcomes by left ventricular ejection fraction in a contemporary heart failure population. Circulation: Heart Failure. 2013 Jul;6(4):635-46.
34. Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction. European Journal of Heart Failure. 2017 Dec;19(12):1606-14.
35. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. Journal of the American College of Cardiology. 2001 Oct;38(4):955-62.
36. Antlanger M, Aschauer S, Kopecky C, Hecking M, Kovarik JJ, Werzowa J, Mascherbauer J, Genser B, Säemann MD, Bonderman D. Heart failure with preserved and reduced ejection fraction in hemodialysis patients: prevalence, disease prediction and prognosis. Kidney and Blood Pressure Research. 2017;42(1):165-76.
37. van Riet EE, Hoes AW, Limburg A, van der Hoeven H, Landman MA, Rutten FH. Strategy to recognize and initiate treatment of chronic heart failure in primary care (STRETCH): a cluster randomized trial. BMC cardiovascular disorders. 2014 Dec;14(1):1-9.
38. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S. Effect of vasodilator therapy on mortality in chronic congestive heart failure. New England Journal of Medicine. 1986 Jun 12;314(24):1547-52.
39. Sonnenberg JL, Sakane Y, Jeng AY, Koehn JA, Ansell JA, Wennogle LP, Ghai RD. Identification of protease 3.4. 24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney. Peptides. 1988 Jan 1;9(1):173-80.
40. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett Jr JC. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. European heart journal. 2013 Mar 21;34(12):886-93.
41. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371:993-1004.
42. Chavey WE, Hogikyan RV, Van Harrison R, Nicklas JM. Heart failure due to reduced ejection fraction: medical management. American Family Physician. 2017 Jan 1;95(1):13-20.
43. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJ, Solomon SD. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA cardiology. 2016 Sep 1;1(6):666-72.
44. Vodovar N, Paquet C, Mebazaa A, Launay JM, Hugon J, Cohen-Solal A. Neprilysin, cardiovascular, and Alzheimer’s diseases: the therapeutic split?. European Heart Journal. 2015 Apr 14;36(15):902-5.
45. Califf RM. The future of cardiovascular medicine from the regulatory perspective. Journal of the American College of Cardiology. 2016 Aug 16;68(7):766-9.
46. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology. 2016 Sep 27;68(13):1476-88.
47. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New England Journal of Medicine. 1996 May 23;334(21):1349-55.
48. Bozkurt B, Khalaf S. Heart failure in women. Methodist DeBakey cardiovascular journal. 2017 Oct;13(4):216.
49. Investigators CI. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. The Lancet. 1999 Jan 2;353(9146):9-13.
50. Bertram Pitt MD, Zannad F, Remme WJ, Cody R, CASTAIGNE A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-17.
51. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, Van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. Journal of the American College of Cardiology. 2005 Aug 2;46(3):425-31.
52. Rogers JK, McMurray JJ, Pocock SJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012 Nov 6;126(19):2317-23.
53. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Östergren J, Yusuf S, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. The Lancet. 2003 Sep 6;362(9386):759-66.
54. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino Jr R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New England Journal of Medicine. 2004 Nov 11;351(20):2049-57.
55. Carson P, Ziesche S, Johnson G, Cohn JN, Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Journal of cardiac failure. 1999 Sep 1;5(3):178-87.
56. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting–enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. New England Journal of Medicine. 2001 May 3;344(18):1351-7.
57. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, Ofili E, Yancy C, Feldman AM, Ghali JK, Taylor AL. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. Journal of cardiac failure. 2009 Apr 1;15(3):191-8.
58. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine. 1999 Sep 2;341(10):709-17.
59. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010 Sep 11;376(9744):875-85.
60. Chavey WE, Hogikyan RV, Van Harrison R, Nicklas JM. Heart failure due to reduced ejection fraction: medical management. American Family Physician. 2017 Jan 1;95(1):13-20.
61. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Beautiful Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008 Sep 6;372(9641):807-16.
62. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2008 Aug 29;372(9645):1223-30.
63. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L. Rosuvastatin in older patients with systolic heart failure. New England Journal of Medicine. 2007 Nov 29;357(22):2248-61.
64. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):1810-52.
65. Buxton AE, Hafley GE, Lehmann MH, Gold M, O’Toole M, Tang A, Coromilas J, Hook B, Stamato NJ, Lee KL. Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease: utility of clinical variables. Circulation. 1999 Apr 13;99(14):1843-50.
66. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. New England Journal of Medicine. 2002 Mar 21;346(12):877-83.
67. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE. Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. New England Journal of Medicine. 2005 Jan 20;352(3):225-37.
68. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. New England Journal of Medicine. 2004 May 20;350(21):2140-50.